about
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolismThe CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic SyndromeEffectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review.Interaction between gemfibrozil and warfarin: case report and review of the literature.Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.Pharmacologic and surgical interventions to improve functional capacity in heart failure.Current drug treatment of hyperlipidemia in older adults.Effectiveness of a Pharmacist-Physician Team-Based Collaboration to Improve Long-Term Blood Pressure Control at an Inner-City Safety-Net Clinic.Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.A review of PCSK9 inhibition and its effects beyond LDL receptors.Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL).Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure.Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study.Considerations for dofetilide use in the elderly.Potassium levels in acute myocardial infarction: definitely worth paying attention to.Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality From Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)".Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).Pharmacists as Integral Members of the Cardiovascular Team.Medication Reconciliation vs Medication Review.Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions.Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).Short-term outcomes of an employer-sponsored diabetes management program at an ambulatory care pharmacy clinic.Pharmacist-physician collaborative care model and time to goal blood pressure in the uninsured population.Safety of enoxaparin bridge therapy in patients with mechanical heart valves.Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review.Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline.Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.A Prescription for Prescribing: Ensuring Continued Pharmacist Preparedness.Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic ReviewCollaborative Drug Therapy Management and Comprehensive Medication Management―2015Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection FractionEffects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diureticsResponse to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738The 2017 American College of Cardiology/American Heart Association hypertension guideline and opportunities for community pharmacistsTreatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 InhibitorsScreening, Identification, and Management of Prediabetes to Reduce Cardiovascular Risk: A Missed Opportunity?
P50
Q26799691-40B7F850-FB66-4AD9-8CB8-28812DF4FE9DQ28082734-2D610A41-F63C-4C79-BC47-1789BB3A0DD5Q30277403-7E40B144-111F-4B38-9B6A-C8ACBE74B32FQ37498881-2DCB745D-3839-4E85-9D72-DBBEE242F190Q38162687-154A4F6B-DE51-4D08-AE93-0012EB153A19Q38272433-F4C6F828-E3D4-4001-86D8-AB89666E3D32Q38338437-9BA64B8D-3AA5-4D0A-8941-62530A0C3CB8Q38750938-6B845844-4152-4039-BAFE-B2ADE0E3B9B1Q38776029-5B28D4FB-D939-4766-8F76-97C324333658Q38966469-37BBA5BC-3CE4-4125-9361-8AED77AF7E92Q39409845-9308EF6F-3451-4FE0-A78E-B8CC52045DEDQ39458225-87918CF7-DCE2-4BE7-A2C8-6A10178C2130Q40346820-6694210F-F955-48F2-A26C-33E19DE5B433Q40780801-8E8F9D6F-3C45-4816-BB41-4655CE197F43Q44996370-AF2D86B3-4818-4697-BA55-1E81D8440D8AQ45040463-61D640E8-FDED-4BF5-9B19-5CF1AA01E9F6Q45047666-4B9028A6-BC2C-4301-A030-40503357E27FQ45058507-59A64FF8-76A5-4991-84F4-510919EF2FC9Q45065864-5FA9EDEF-38DB-46C6-BD10-F143529D88B4Q45067204-BDFBBCF2-D88F-4A12-9898-6330F0CDCB05Q45068364-7AB262A1-6D3A-4E6E-A71F-9D4B8220CD3DQ45069532-F5F3825C-9317-4E98-A39E-F9957C21C571Q45073053-4B607072-195F-4D14-8B35-2CB65C5BB96AQ45248116-E7EDFE3D-9680-444C-8002-F48DD381B384Q46054816-AF42B60D-335D-42DE-AD53-380FBBABEE9BQ46879234-C530CAC6-AEC9-4E43-9E2E-174B0C0A8A00Q47096165-26E41433-2C30-4811-9E60-575716DB3913Q47659908-578204FB-22BB-49BC-A2B1-19D1A1129C8DQ47668850-6A3D9952-2454-4426-94F6-17C87E9B46EEQ47769899-584E064E-1806-4C98-B755-B083C2303F04Q50102197-836D600F-BC63-4F97-9433-FF6A3D73A7A0Q52668978-1FFA94F1-9C07-4249-B1D0-7DCD358518F7Q57539852-066661FC-80D6-4988-81F4-BD67284E60AEQ60016964-C9D837A5-0762-4805-8C1E-B763C9DC42D9Q60177601-8B08C0EF-3AE5-4B6E-B032-F0FEA45EEA22Q88231385-63751285-7AA3-413C-B261-A87F714307C0Q88763424-F8F6933B-CF13-472B-92CF-B2F29FF5120DQ88876069-0AE3FF55-860E-4AF0-9D3D-3D1591F3BECEQ89748613-DF3E45F7-21F8-4128-9748-8F6507EC2B55Q90724205-184DA733-FCAA-4CA7-97C4-35C5C1A8AB70
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dave Dixon
@ast
Dave Dixon
@en
Dave Dixon
@es
Dave Dixon
@nl
Dave Dixon
@sl
type
label
Dave Dixon
@ast
Dave Dixon
@en
Dave Dixon
@es
Dave Dixon
@nl
Dave Dixon
@sl
prefLabel
Dave Dixon
@ast
Dave Dixon
@en
Dave Dixon
@es
Dave Dixon
@nl
Dave Dixon
@sl
P1053
P-3676-2017
P106
P21
P31
P3829
P3835
dave-dixon
P496
0000-0001-7560-9521